Shots:

• ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development- commercialization milestones along with royalties on sales
• The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044
• ACP-044 has demonstrated a promising effect in the P-I study with an anticipated initiation of P-II study in H1’21. The novel RSDAx MOA interferes with multiple pain pathways treating pain simultaneously

­ Ref: ACADIA | Image: San Diego Business Attorney